Overview

Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety of MTS in the symptomatic treatment of children aged 6-12 diagnosed with ADHD
Phase:
Phase 3
Details
Lead Sponsor:
Noven Therapeutics
Collaborator:
Noven Pharmaceuticals, Inc.
Treatments:
Methylphenidate